[Sigsti-l] FW: Moving Biotech Research to ProfitableCommercialization]

[K. T. Vaughan]

Hi all - Gene sent this out to the sigmetrics list and I thought it
might be of interest to the STI and BIO peeps as well.  Sorry for
duplication, if any.  KT

"Garfield, Eugene" wrote:

>  fyi best wishes. Gene Garfield. I have no connection with this
> symposium
> [Garfield, Eugene] -----Original Message-----
> From: World Genomics Symposium [mailto:info at escienceinfo.com]
> Sent: Monday, August 26, 2002 4:06 PM
> To: garfield at dsl.cis.upenn.edu
> Subject: Moving Biotech Research to Profitable Commercialization
>  Register today to visit World Genomics Symposium and Exposition,  in
> Atlantic City's new
> convention center September 18,  19 or 20th by using priority code
> SC2 for free expo and
> poster session admittance. Take one day or all three event days to
> network with other
> leading scientists and corporate leaders to focus on the tools and
> technology used in
> moving your research or bio-pharma company to the next level of
> commercialization.
> Register at http://www.world-genomics.com/registration.
>
> Seek out partnership opportunities, see new technologies and learn
> from industry leaders
> such as:
>
>    * Bill Haseltine, PhD, CEO, Human Genome Sciences;
>    * Carl Foster, PhD,  Sr VP, Oxford Glycosciences;
>    * Jasmine Gruia-Gray, PhD, Dir Proteomics, Amersham Biosciences;
>    * Mary Konsolaki, PhD,Program Head, Functl Genomics, Novartis
>      Pharmaceuticals;
>    * Christine Foster, PhD, VP, Pharmacogenomics, DNA Sciences;
>    * Chris McLeod, PhD, EVP, CuraGen Corp.
>    * David Goodlett, PhD, Dir Proteomics, Institute for Systems
>      Biology;
>    * Francis Kalush, PhD, Dir, Pharmacogenomics, Celera
>      Diagnostics....
>
> And over 55 more leaders in the bio-pharma world.
>
> Conference registration available at $100 off when using priority code
> SC2 before
> September 3rd to register at
> http://www.world-genomics.com/registration
>
> See you in Atlantic City in September!
>
> Please forward this email to any colleagues who might be interested.
> ____________________________________________________________________
> ___________
>